ArticleCancer science2026
Precision Oncology for Pediatric Solid Tumors Using In-Hospital Pediatric/AYA Malignancy-Specific Panel Sequencing.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Precision oncology, based on the genomic profile of tumors, is increasing in cancer treatment. It is important in pediatric and adolescent and young adult (AYA) malignancies, a group of rare cancers that are difficult to diagnose and progress quickly. We evaluated the usefulness of in-hospital molecular profiling using a specific sequencing panel for pediatric and AYA malignancies in clarifying the diagnosis, predicting the prognosis, and identifying therapeutic targets. We evaluated the Oncomine Childhood Cancer Research Assay (203 genes, 1700 fusions) and analyzed 153 samples at diagnosis and 34 samples at relapse or refractory from 165 pediatric and AYA patients with various solid malignancies, including neuroblastoma, hepatoblastoma, brain tumor, and sarcoma. We simulated in-hospital molecular profiling. In total, 320 reportable variants were identified in 153 samples (81.8%). Variants with clinical significance were identified in 62 samples (33.1%), including diagnostic variants in 26 (13.9%), prognostic variants in 17 (9%), targetable variants in 41 (21.9%), and variants with drug resistance in 18 (9.6%). Additionally, 62.0% and 94.1% of identified diagnostic and prognostic variants, respectively, had high levels of evidence. In five patients with cancer predisposition syndromes, all pathogenic germline mutations were validated. The turnaround time (TAT) from sample collection to reporting of the molecular profile was within seven working days. In-hospital molecular profiling using a sequencing panel specified tailored for pediatric and AYA malignancies has a high rate of identifying reportable variants and enables accurate diagnosis, malignancy grading, and treatment selection, as well as cancer predisposition syndromes with a short TAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.